City Therapeutics
The VP Controller will lead global accounting operations, financial reporting, and internal controls for City Therapeutics, guiding the company’s transition toward a public company. Reporting to the CFO, this role will build a public‑ready accounting team, implement SOX‑compliant systems, and oversee SEC filing preparation.
Company Size
1-10 employees
City Therapeutics is a biotechnology company focused on developing therapeutics for respiratory and lung diseases. The company concentrates on creating targeted, locally delivered treatments—often inhaled or airway-directed biologics and small molecules—to improve efficacy and reduce systemic side effects. City Therapeutics advances candidates from discovery through development and collaborates with academic and industry partners to translate respiratory science into clinical-stage medicines. Their mission is to transform care for patients with unmet needs in pulmonary and inflammatory disorders.
City Therapeutics Pursues ‘Next Generation of RNAi’
2 weeks ago
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
May 27, 2025
City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases
Nov 11, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for City Therapeutics.
83% above the average for this role
Biogen maps out $1B biobucks deal with RNAi-focused City Therapeutics
May 27, 2025